MoonLake Immunotherapeutics - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
MLTX Nasdaq 2834 www.moonlaketx.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for MoonLake Immunotherapeutics

MLTX Stock Under Pressure As Investors Await Psoriatic Arthritis Trial Data - Aug 3rd, 2026 11:30 am
Wall Street Analysts See a 73.35% Upside in MOONLAKE IMMUNO (MLTX): Can the Stock Really Move This High? - Jul 31st, 2026 7:55 am
SLS Vs MLTX: Retail Traders Race To Pick Merck’s Next Biotech Buyout As Keytruda’s $31.7B Patent Cliff Nears - Jul 12th, 2026 8:48 pm
MoonLake Immunotherapeutics' CFO Sells 39K Shares - Jul 3rd, 2026 8:34 am
MoonLake Immunotherapeutics (MLTX) Outlook Strengthens as Analysts See Major Opportunity in Hidradenitis Suppurativa - Jun 30th, 2026 7:22 am
How Investors May Respond To MoonLake Immunotherapeutics (MLTX) VELA Data And Upsized Follow-On Offering - Jun 25th, 2026 6:07 am
Why MoonLake Immunotherapeutics Stock Wilted on Wednesday - Jun 24th, 2026 6:09 pm
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Wednesday Amid Easing US-Iran Tensions - Jun 24th, 2026 7:17 am
MLTX Stock Extends Pullback After Biggest Rally In Over 6 Months Following Skin Disease Trial Data — A Look At The Latest Development - Jun 24th, 2026 5:48 am
MoonLake Immunotherapeutics Announces Pricing of Upsized $200 Million Public Offering - Jun 23rd, 2026 9:08 pm
MLTX Stock Clocks Best Day In Over 6 Months — What’s Driving The Investor Optimism? - Jun 22nd, 2026 2:59 pm
MoonLake Immunotherapeutics Announces Proposed Public Offering - Jun 22nd, 2026 2:01 pm
Why Is MLTX Stock Rallying Nearly 20% Overnight? - Jun 21st, 2026 6:52 pm
MoonLake Announces Week 52 Results of Sonelokimab from its Phase 3 VELA Program in Hidradenitis Suppurativa and Confirms Investor Day on June 22, 2026 - Jun 21st, 2026 3:00 pm
MLTX Stock Moves Higher As Traders Position For Late-Stage Trial Catalysts - Jun 17th, 2026 11:29 am
Why Did MLTX Stock Rise After-Hours Today? - Jun 8th, 2026 7:17 pm
MoonLake Immunotherapeutics CFO Trims His Stake. Should Investors Be Concerned? - Jun 4th, 2026 8:19 pm
MoonLake Immunotherapeutics (MLTX) Price Target Raised to $45 At H.C. Wainwright on FDA Progress - Jun 2nd, 2026 7:55 am
MoonLake Immunotherapeutics (MLTX) Is Up 7.3% After FDA Aligns on Sonelokimab BLA Pathway - May 12th, 2026 10:17 am
MoonLake Clears A Key Regulatory Hurdle, And Shares Rocket - May 11th, 2026 2:15 pm